71 results
8-K
EX-99.1
AXLA
Axcella Health Inc.
30 Mar 23
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
8:22am
-blind, placebo-controlled investigation evaluated the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID. The study, which did
8-K
EX-10.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
have the meaning ascribed to such term in Section 4.9(e).
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without … limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.
“Prospectus” means the prospectus
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
in the Phase 2a trial began in December 2021.
The Phase 2a trial was a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy … in the second quarter of 2021. This global randomized, double-blind, placebo-controlled, multi-center investigation evaluated the efficacy and safety
8-K
EX-10.1
sl2cb2lk5yeh8dch eo
23 Sep 22
Entry into a Material Definitive Agreement
4:01pm
8-K
ys1y1ux2 4vkmj
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
6799eom
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
9uiatcyi29tlvy6
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
EX-10.1
ux04jjv0vtkkzq
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
rgkzwxn3
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
kj7aa1voxaud4w5c49t
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
a8wlz3giyk4o4i rqb
10 Jan 22
Other Events
8:00am
8-K
9b2xbkk1 0kz8dp2
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-10.1
6zq8hlh5
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-99.1
5t5v1
7 Dec 21
Departure of Directors or Certain Officers
6:15am